Cancer News and Research

Latest Cancer News and Research

Functional MRI illuminates brain networks activated by motion

An estimated 300,000 people in North America are afflicted with dystonia, a disorder characterized by a progressive loss of motor control. Patients with generalized dystonia grapple with involuntary muscle spasms that lead to uncontrolled twisting and turning in awkward, sometimes painful postures.

14 Nov 2011

Cancer drug joins list of medicines in short supply

A crucial cancer drug has been in short supply since midsummer - and its maker, Johnson & Johnson Inc., has not been able to remedy the situation since.

14 Nov 2011

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions.

14 Nov 2011

Cerulean to present positive CRLX101 progression-free survival time results at 2011 AACR-NCI-EORTC

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the presentation of clinical and non-clinical data on its lead product candidate, CRLX101, at the 2011 AACR-NCI-EORTC International Conference taking place from November 12-16 in San Francisco, California.

14 Nov 2011

Cord Blood America third quarter revenues increase 56% to $1.49 million

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced revenues for the nine months ended September 30, 2011 totaled $4.38 million, up 59 percent compared to revenues of $2.75 million in the same period in 2010.

14 Nov 2011

Simcere third quarter total revenue decreases 8.9% to RMB501.0 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended September 30, 2011.

14 Nov 2011

Leonardo Biosystems receives second investment from Texas Emerging Technology Fund

Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010.

14 Nov 2011

EntreMed third quarter net loss decreases to $1.3 million

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2011.

14 Nov 2011

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Oncolytics Biotech Inc. today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

14 Nov 2011

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

First Edition: November 14, 2011

In today's headlines, reports about the Supreme Court's expected health law announcement; about where things stand with the super committee and its fast-approaching deadline; and other health policy news.

14 Nov 2011

Luminescent upconversion nanocrystals can detect cancer cells

Upconversion emission materials are ideal for bioimaging due to its effectiveness as contrast agents for the detection of cancer cells, more so when the background emission of non-cancerous tissues can be minimised. These materials could be used as biomarkers for luminescent labeling of cancerous cells. Opaque tissues can be turned into glassy, transparent substances by using these biomarkers which rely on near-infrared excitation.

14 Nov 2011

First study to look at alcohol consumption in adolescents and risk of breast disease

Adding to research linking alcohol to breast cancer risk, a new study from Washington University School of Medicine in St. Louis shows that adolescent girls with a family history of breast disease - either cancer or the benign lesions that can become cancer - have a higher risk of developing benign breast disease as young women than other girls. And unlike girls without a family history, this already-elevated risk rises with increasing alcohol consumption.

14 Nov 2011

Study uses fMRI to assess changes in brain after exercise intervention

Areas of the brain responsible for pain processing and cognitive performance changed in fibromyalgia patients who exercised following a medication holiday, say researchers from Georgetown University Medical Center. They say the changes indicate brain functioning is more streamlined after an exercise intervention because less of the brain-s resources is devoted to processing bothersome fibromyalgia perceptions such as pain.

14 Nov 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

In the last three decades, thousands of women with breast cancer have taken the drug tamoxifen, only to discover that the therapy doesn't work, either because their tumors do not respond to the treatment at all, or because they develop resistance to it over time. Now researchers at the University of California, San Francisco (UCSF) have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it.

14 Nov 2011

Scientists create new phenotypic cancer drug screening platform

Researchers have created a new phenotypic screening platform that better predicts success of drugs developed to prevent blood vessel tumor growth when moving out of the lab and onto actual tumors.

14 Nov 2011

New-onset AF, severe sepsis may increase risk of stroke and mortality in hospital settings

A recent study led by researchers at Boston University School of Medicine (BUSM) shows an increased risk of stroke and mortality among patients diagnosed with severe sepsis and new-onset atrial fibrillation (AF) during hospitalization.

14 Nov 2011

Scientists identify factors that lead to concomitant tumor resistance

Scientists are another step closer to understanding what drives tumor metastasis, as laboratory models suggest there are factors inside tumors that can slow their own growth.

14 Nov 2011

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

14 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Cancer News and Research

Latest Cancer News and Research

Functional MRI illuminates brain networks activated by motion

Cancer drug joins list of medicines in short supply

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

Cerulean to present positive CRLX101 progression-free survival time results at 2011 AACR-NCI-EORTC

Cord Blood America third quarter revenues increase 56% to $1.49 million

Simcere third quarter total revenue decreases 8.9% to RMB501.0 million

Leonardo Biosystems receives second investment from Texas Emerging Technology Fund

EntreMed third quarter net loss decreases to $1.3 million

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Soligenix third quarter revenues increase to $5,796,000

First Edition: November 14, 2011

Luminescent upconversion nanocrystals can detect cancer cells

First study to look at alcohol consumption in adolescents and risk of breast disease

Study uses fMRI to assess changes in brain after exercise intervention

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

Scientists create new phenotypic cancer drug screening platform

New-onset AF, severe sepsis may increase risk of stroke and mortality in hospital settings

Scientists identify factors that lead to concomitant tumor resistance

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in